As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.
14 Analysts have issued a 89bio Inc forecast:
14 Analysts have issued a 89bio Inc forecast:
| Jun '25 | 
         
    +/-
   
  
    %
   
 | 
      ||
| Revenue | - - | 
         
    -
 
        
       | 
      |
| Gross Profit | - - | 
         
    -
 
        
       | 
      |
| EBITDA | -467 -467 | 
         
      
        
        144%
      
      
        
        144%
      
 
        
       | 
      |
| EBIT (Operating Income) EBIT | -467 -467 | 
         
      
        
        144%
      
      
        
        144%
      
 
        
       | 
      |
| Net Profit | -450 -450 | 
         
      
        
        158%
      
      
        
        158%
      
 
        
       | 
      |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
| Head office | United States | 
| CEO | Rohan Palekar | 
| Employees | 93 | 
| Founded | 2018 | 
| Website | www.89bio.com | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


